MedTrace Logo

China Lymphoma Patient Registry Study

NCT03313271 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2017-10-18

No results posted yet for this study

Summary

Lymphoma is the most common hematologic tumor. It is derived from lymphoid tissue, including Hodgkin's lymphoma(HL) and non Hodgkin's lymphoma(NHL). The treatment of lymphoma includes chemotherapy, radiotherapy, stem cell transplantation, targeted therapy and surgery etc. With the progress of treatment, the survival rate of lymphoma patients has been improved. But the 5 year survival rate of lymphoma in China is shorter than that in United States. The reason is that there is still a gap between China and the United States in disease screening, diagnosis and treatment.

Observational studies, especially cohort studies, are important tools for understanding disease progression, treatment, and prognosis in the real world. Observational cohort studies which involve over 500 patients are currently launched by South Korea and the United States. China, which has more patients, doesn't have a cohort of patients with lymphoma. So the primary objective of this study was to establish an observational cohort of patients with lymphoma in China and follow up the patients for a long period of time to provide basic support for clinical research and drug development, and continuously improve patient outcomes and quality of life. The secondary objective is to collect information about diagnosis, treatment, follow-up and prognosis of lymphoma.

Conditions

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Tianjin Medical University Cancer Hospital

    collaborator UNKNOWN

  • Zhejiang Cancer Hospital

    collaborator OTHER

  • Heilongjiang Cancer Hospital

    collaborator UNKNOWN

  • Sipai(Beijing)Network Technology Co Ltd

    collaborator UNKNOWN

  • Jun Zhu

    lead OTHER

Principal Investigators

  • Jun Zhu, Ph D · Peking University Cancer Hospital & Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-17
Primary Completion
2027-05-17
Completion
2027-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03313271 on ClinicalTrials.gov